Clinical Efficacy of Self-made Compound Danshen Formula Combined with Rux-olitinib in Treatment of Patients with Myelofibrosis and Its Influence on Quality of Life
Objective To investigate the clinical efficacy of self-formulated Compound Danshen Formula com-bined with ruxolitinib in the treatment of patients with myelofibrosis and its impact on their quality of life(QOL).Methods Ninety patients with myelofibrosis who were admitted to The First Hospital of Xingtai between October 2017 and December 2020 were selected and randomly divided into a control group and a study group according to a random number table,with 45 patients in each group.The control group was treated with ruxolitinib phosphate tablets,while the study group received the Compound Danshen Formula in addition to the treatment given to the control group.Both groups were treated for six months.The clinical efficacy,improvement rate of myelofibrosis,incidence of adverse reactions,pre-and post-treatment scores on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score(MPN-SAF-TSS),spleen size(length and thickness),blood routine indices[white blood cell count(WBC),platelet(PLT),hemoglobin(Hb)],and QOL scores were observed and compared between the two groups.Results After treatment,the effective rate in the study group was 75.56%(34/45),significantly higher than 55.56%(25/45)in the control group(P<0.05).The improvement rate of myelofibrosis in the study group was 64.44%(29/45),significantly higher than 42.22%(19/45)in the control group(P<0.05).Post-treatment MPN-SAF-TSS scores were significantly lower in both groups compared to pre-treatment(P<0.05).The MPN-SAF-TSS score of the study group was significantly lower than that of the control group(P<0.05).The length and thickness of the spleen in both groups were significantly reduced post-treatment compared to pre-treatment(P<0.05).The spleen length and thickness of the study group were significantly smaller than those of the control group(P<0.05).Post-treatment WBC and PLT levels were significantly lower,and Hb levels were significantly higher in both groups compared to those before treatment(P<0.05).The WBC and PLT levels of the study group were significantly lower,and Hb levels were significantly higher than those of the control group(P<0.05).Post-treatment QOL scores were significantly higher in both groups compared to those before treatment(P<0.05).The QOL scores of the study group were significantly higher than those of the control group(P<0.05).During the treatment period,the incidence of adverse reactions was 17.78%(8/45)in the study group and 20.00%(9/45)in the control group,with no statistically significant difference(P>0.05).Conclusion The combination of the self-formulated Compound Danshen Formula with ruxolitinib in the treatment of myelofibrosis can alleviate clinical symptoms,reduce spleen size,improve blood routine indi-ces,decrease the degree of myelofibrosis,enhance QOL,and is highly safe.
Danshen(Salviae Miltiorrhizae Radix et Rhizoma)Chinese Medicine PrescriptionRuxolitinibMy-elofibrosis